Gilead­'s new­ly de­part­ed R&D chief re-emerges as CEO of a ri­val hep B biotech look­ing to make a come­back

Just a few weeks af­ter tak­ing his $1.1 mil­lion sev­er­ance check from Gilead, John McHutchi­son has re-emerged as the new CEO of As­sem­bly Bio­sciences $ASMB, which has seen its share price swoon as in­vestors lost con­fi­dence in its abil­i­ty to com­pete with Gilead with its ex­per­i­men­tal he­pati­tis B drug.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER